Mutation T315I - Chronic Myeloid Leukemia- CML
CLINICAL TRIAL DRUGS
DCC-2036 (Rebastinib) by Deciphera
KW-2449 by Kyowa Hakko Kirin Pharma, Inc
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
DCC-2036 (Rebastinib) by Deciphera
KW-2449 by Kyowa Hakko Kirin Pharma, Inc
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
ARTICLES
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
July 22, 2019, Biospace
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
2018, Blood Journal
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
December 3, 2018, ASH 2018
Clinical features and outcomes in chronic myeloid leukemia with T315I mutation
July 31, 2017, Cellular Therapy and Transplantation
Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells
2016, Journal Blood
Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation
December 7, 2015, OncologyNurseAdvisor
Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
January 28, 2015, NCBI
BCR-ABL Point Mutations and TKI Treatment in CML Patients
July 8, 2014, SciMedCentral
Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia
January 10, 2014, OncLive
The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
May 28, 2013, Haematologica
Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical
Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing: Detection of the T315I Mutation in Bone Marrow CD34+ Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood
June 1, 2012, PubLMed
Ascentage Pharma to Initiate Phase Ib Study of HQP1351 in Tyrosine Kinase Inhibitors -resistant Chronic Myeloid Leukemia Patients in the US
July 22, 2019, Biospace
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
2018, Blood Journal
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
December 3, 2018, ASH 2018
Clinical features and outcomes in chronic myeloid leukemia with T315I mutation
July 31, 2017, Cellular Therapy and Transplantation
Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells
2016, Journal Blood
Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation
December 7, 2015, OncologyNurseAdvisor
Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
January 28, 2015, NCBI
BCR-ABL Point Mutations and TKI Treatment in CML Patients
July 8, 2014, SciMedCentral
Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia
January 10, 2014, OncLive
The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis
May 28, 2013, Haematologica
Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical
Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing: Detection of the T315I Mutation in Bone Marrow CD34+ Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood
June 1, 2012, PubLMed
Novel potent inhibitor (P2745) of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines (included T315I)
April 2, 2012, AACR Annual Meeting 2012
April 2, 2012, AACR Annual Meeting 2012
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
January 20, 2012, International Journal of Hematology
A clinical Trial ( Mutation T315I) and a Growing Family - Hans Loland VIDEO
November 18, 2011, Patient Power
Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data
June 12 2011, EHA 2011
A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
April 12, 2011, Journal of clinical pathology
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
April 12, 2011, Cancer cell
Ariad, MolecularMD Partner on Companion Dx for T315I Mutation
March 28, 2011, genomeweb
HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
March 24, 2011, Clinical Cancer Research
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
November 17, 2010, Clinical Cancer Research
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
November 15, 2010, Cancer Research
The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge
March 3, 2010, Clinical Lymphoma, myeloma & Leukemia
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutatedBCR/ABL translocation
May 28, 2009, Journal Blood
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
December 10, 2008, Medical News Today
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
December 8, 2008, ASH2008
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
March 6, 2008, Clinical Cancer Research
January 20, 2012, International Journal of Hematology
A clinical Trial ( Mutation T315I) and a Growing Family - Hans Loland VIDEO
November 18, 2011, Patient Power
Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbour the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data
June 12 2011, EHA 2011
A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation
April 12, 2011, Journal of clinical pathology
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036
April 12, 2011, Cancer cell
Ariad, MolecularMD Partner on Companion Dx for T315I Mutation
March 28, 2011, genomeweb
HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
March 24, 2011, Clinical Cancer Research
Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010, MD Anderson Cancer Center - Department of Leukemia
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
November 17, 2010, Clinical Cancer Research
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile
November 15, 2010, Cancer Research
The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge
March 3, 2010, Clinical Lymphoma, myeloma & Leukemia
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutatedBCR/ABL translocation
May 28, 2009, Journal Blood
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
December 10, 2008, Medical News Today
Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor
December 8, 2008, ASH2008
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
March 6, 2008, Clinical Cancer Research
